Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats
Date
2017
Authors
Johnston, I.
Tan, M.
Cao, J.
Matsos, A.
Forrest, D.
Si, E.
Fardell, J.
Hutchinson, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Behavioural Brain Research, 2017; 334:109-118
Statement of Responsibility
Ian N. Johnstona, Manuela Tana, Jacob Caoa, Antigone Matsosa, Daniel R.L. Forresta, Emily Sia, Joanna E. Fardella, Mark R. Hutchinsonc
Conference Name
Abstract
Chemotherapy can cause serious neurotoxic side effects, such as painful peripheral neuropathies and disabling cognitive impairments. Four experiments examined whether Ibudilast, a clinically approved neuroimmune therapy, would reduce tactile allodynia and memory impairments caused by oxaliplatin in laboratory rats. Rats received an intraperitoneal injection of oxaliplatin (6mg/kg i.p.) or vehicle and were assessed for tactile allodynia 3 or 5days after injection, memory impairments in the novel object and novel location recognition tests 10-12days after injection, and fear conditioning 14days after injection. Ibudilast (7.5mg/kg) or vehicle was administered prior to oxaliplatin (Experiments 1 and 3) or prior to behavioural testing (Experiments 2 and 4). Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments. Ibudilast treatment prior to behavioural testing reduced oxaliplatin-induced tactile allodynia, memory impairments, and impaired renewal of fear conditioning. These results suggest that Ibudilast could be an effective treatment against oxaliplatin-induced neuropathies and cognitive impairments.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2017 Elsevier B.V. All rights reserved.